(Q70758590)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

title

Complement activation during OKT3 treatment: a possible explanation for respiratory side effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

author name string

M H Raasveld

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

F J Bemelman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

P T Schellekens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

F N van Diepen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

A van Dongen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

E A van Royen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

C E Hack

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

I J ten Berge

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

language of work or name

English

0 references

publication date

1 May 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

page(s)

1140-1149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.1993.160

13 October 2019

exact match

0 references

cites work

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

OKT3 and pulmonary capillary permeability.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

OKT3 and cerebral oedema

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5).

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Thromboembolic complications and dose of monoclonal OKT3 antibody

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Role of complement activation in a model of adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Systemic complement activation, lung injury, and products of lipid peroxidation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Interleukin-6 and neopterin in renal transplant recipients: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Muromonab CD3. A review of its pharmacology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Continuous cell activation is necessary for stable interaction of complement receptor type 3 with its counter-structure in the aggregation response of human neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Advantages of rat monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Transient adhesion of neutrophils to endothelium

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Release of inflammatory mediators from stimulated neutrophils.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Tissue destruction by neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1993.160

7 January 2021

Identifiers

DOI

10.1038/KI.1993.160

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8510394%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

1 reference